profit from every CN¥100 of sales.
CN¥0CN¥100
BeOne Medicines
CN¥280.20-2.58% today
+0.5% in 1 year
1-year low CN¥208.001-year high CN¥313.31
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay CN¥217.39 for every CN¥1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
BeOne Medicines vs. similar companies
BeOne Medicines grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from CN¥100 of sales | Sales growth a year | Price per CN¥1 of profit |
|---|---|---|---|
| BeOne Medicines | 217.4× · Very expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads BeOne Medicines's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 217.4×
- –
- –
- 12.7×
- 11.7×
- 72.4×
- –
- 1.4%
- 0.5%
- –
Profitability
- 87.5%
- 8.4%
- 5.4%
- –
- 6.5%
- -10.7%
- –
- –
- –
- –
Growth
- +55.7%
- –
- –
- –
- +3.2%
Financial health
- -5.6×
- 0.25
- –
- 8.2×
- 3.41
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 44%of 946
Bottom 48%of 872
Bottom 2%of 565
Top 12%of 867
Top 49%of 986
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
41No pass
Philip Fisher
54No pass
Peter Lynch
83Pass
Joel Greenblatt
4No pass
Charlie Munger
39No pass
Terry Smith
42No pass
Questions about BeOne Medicines
Is BeOne Medicines a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BeOne Medicines AI analysis
What does BeOne Medicines do?
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. It is in Biotechnology.
Is BeOne Medicines stock halal?
Yes. BeOne Medicines passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has BeOne Medicines stock done over the past year?
Up 0.5% over the past twelve months, to CN¥280.20. It traded between CN¥208.00 and CN¥313.31 and is 10.6% below its high.
Who are BeOne Medicines's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BeOne Medicines's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.